In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Undefined product Cortexin (cortical polypeptide complex) | Mixture Cerebrolysin | |
|---|---|---|---|
| Identity | |||
| Kind | Undefined product | Mixture | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 252 | 1,781 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 18 (14 in people) | 109 (96 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 41 · 9 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cortexin (cortical polypeptide complex) | Cerebrolysin |
|---|---|---|
| NeuroprotectionNervous system and cognition | 9233509 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| Cognition and memoryNervous system and cognition | 48435 | 26517293 |
|---|
| Exercise and physical functionNervous system and cognition | 1284 | 14610343 |
|---|
| Adverse eventsWhole body | 191531 | 959041 |
|---|
| Receptor activity and mechanismPharmacology | 14149 | 2232312377 |
|---|
| Overall treatment effectWhole body | 55 | 3535 |
|---|
| Immune responseImmune and inflammation | 651 | 3724310 |
|---|
| Anxiety and moodMental health and mood | 14104 | 261313 |
|---|
| Inflammation markersNervous system and cognition | 1165 | 508366 |
|---|
| PainNervous system and cognition | 33 | 24519 |
|---|
| Speech and languageNervous system and cognition | 11 | 1010 |
|---|
| Oxidative stressNervous system and cognition | 523 | 2727 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cortexin (cortical polypeptide complex) | Cerebrolysin |
|---|---|---|
| Overall treatment effectNervous system and cognitionCompared as: value in the arm that got the peptide, in score | No comparable result 2 randomized-trial results measure it in another way or another unit. | 2.84 score CIBIC+ Placebo: 3.68 score Dose studied: 20 mLn = 2422011 |
| Anxiety and moodMental health and moodCompared as: value in the arm that got the peptide, in fold | −1.6 fold HADS anxiety decrease · Shown as a change. The study reports a hads anxiety decrease of this size. Dose studied: 10 mgten dosesn = 1102026 | |
| PainNervous system and cognitionCompared as: value in the arm that got the peptide, in fold | −2.2 fold Numbness decrease · Shown as a change. The study reports a numbness decrease of this size. Control group: −1.3 fold Dose studied: 10 mgten dosesn = 1102026 | |
| Cognition and memoryNervous system and cognitionCompared as: difference from placebo, in p value | No comparable result 10 randomized-trial results measure it in another way or another unit. | 0.02 p value ADAS-Cog comparison p value Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000 |
| Adverse eventsWhole bodyCompared as: share of people in the arm that got the peptide, in % | No comparable result 4 randomized-trial results measure it in another way or another unit. | 85% Treatment completion proportion · Cerebrolysin (G1) Saline (G2): 90% Dose studied: 20 mln = 402016 |
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in points | No comparable result 5 randomized-trial results measure it in another way or another unit. | 2.3 points ALSFRS-R change Placebo decrease: 0.9 points Dose studied: 10 mL once daily, five days a week for the first month and three days a week for the next two months1 monthn = 202023 |
| Inflammation markersNervous system and cognitionCompared as: value in the arm that got the peptide, in lesions | No comparable result 6 randomized-trial results measure it in another way or another unit. | 14 lesions Gadolinium-positive lesion count Dose studied: 20 mln = 42016 |
| NeuroprotectionNervous system and cognitionCompared as: difference from placebo, in points | No comparable result 6 randomized-trial results measure it in another way or another unit. | 2.085 points Difference in decreases 10-day cycles over 3 intervalsn not reported2025 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | 7.3% HbA1c Control group: 7.8% Dose studied: 10 mgten dosesn = 1102026 |
No comparable result
2 randomized-trial results measure it in another way or another unit.
2.84 score
CIBIC+
Placebo: 3.68 score
Dose studied: 20 mLn = 2422011
No comparable result 2 randomized-trial results measure it in another way or another unit. |
No comparable result 2 randomized-trial results measure it in another way or another unit. |
No randomized trial result 5 results from other study designs. |
−1.6 fold
HADS anxiety decrease · Shown as a change. The study reports a hads anxiety decrease of this size.
Dose studied: 10 mgten dosesn = 1102026
No comparable result
2 randomized-trial results measure it in another way or another unit.
−2.2 fold
Numbness decrease · Shown as a change. The study reports a numbness decrease of this size.
Control group: −1.3 fold
Dose studied: 10 mgten dosesn = 1102026
No comparable result
2 randomized-trial results measure it in another way or another unit.
No comparable result
10 randomized-trial results measure it in another way or another unit.
0.02 p value
ADAS-Cog comparison p value
Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000
No comparable result
4 randomized-trial results measure it in another way or another unit.
85%
Treatment completion proportion · Cerebrolysin (G1)
Saline (G2): 90%
Dose studied: 20 mln = 402016
No comparable result
5 randomized-trial results measure it in another way or another unit.
2.3 points
ALSFRS-R change
Placebo decrease: 0.9 points
Dose studied: 10 mL once daily, five days a week for the first month and three days a week for the next two months1 monthn = 202023
No comparable result
6 randomized-trial results measure it in another way or another unit.
14 lesions
Gadolinium-positive lesion count
Dose studied: 20 mln = 42016
No comparable result
6 randomized-trial results measure it in another way or another unit.
2.085 points
Difference in decreases
10-day cycles over 3 intervalsn not reported2025
7.3%
HbA1c
Control group: 7.8%
Dose studied: 10 mgten dosesn = 1102026
No randomized trial result
5 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Cortexin (cortical polypeptide complex) found in ClinicalTrials.gov.
Top 3 of 41 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ever Neuro Pharma GmbH242 participantsOct 2006 to Aug 2007
Vascular Dementia
Ever Neuro Pharma GmbH1,071 participantsSept 2006 to Feb 2011
Ischemic Stroke
Poznan University of Medical Sciences350 participants10 Jan 2023 to est. 31 Mar 2025
Acute Ischemic Stroke
2 more mention it but do not test it. They only measure it or name it in their text.